登入選單

返回Google圖書搜尋

Abatacept Retention and Clinical Outcomes in Rheumatoid Arthritis: Real-world Data from the German Cohort of the ACTION Study and a Comparison with Other Participating Countries

Rieke AltenEugen FeistHanns-Martin LorenzHubert G. NüßleinReinhard VollMelanie ChartierYedid ElbezChristiane Rauch

出版	Universität, 2019
URL	http://books.google.com.hk/books?id=EpQ_zQEACAAJ&hl=&source=gbs_api

註釋

Abstract: Introduction
AbataCepT In rOutiNe clinical practice (ACTION; NCT02109666) was an observational study of patients with rheumatoid arthritis who initiated intravenous abatacept in clinical practice. We aimed to compare abatacept retention rates and clinical outcomes in patients from Germany versus other countries.

Method
Baseline characteristics, crude retention rates, and clinical outcomes were compared by treatment line in the German cohort at 2 years. In addition, biologic-naïve patients were compared with biologic-naïve patients pooled from other participating countries.

Results
In the German cohort, 677/680 (99.6%) patients enrolled were evaluable and 171/677 (25.3%) were biologic naïve. At baseline, abatacept monotherapy was received by a similar proportion of biologic-naïve and biologic-failure patients in the German cohort, but by a greater proportion of biologic-naïve patients in German versus other countries cohort (27.5 vs. 12.9%). The overall crude abatacept retention rate at 2 years in the German cohort was 39.9%; retention rate did not differ significantly by treatment line, but among biologic-naïve patients it was lower in Germany than in the other countries cohort (42.1 vs. 58.7%; log-rank test p 0.001). At 2 years, good/moderate European League Against Rheumatism (EULAR) response rates in biologic-naïve patients were 85.5% in the German and 92.1% in other countries cohort (p = 0.163).brbrConclusions